Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neurotech International ( (AU:NTI) ) has provided an update.
Neurotech International has reported that clinical and mechanistic data for its proprietary medicinal cannabis‑derived drug NTI164 in paediatric acute‑onset neuropsychiatric syndrome (PANS) have been published in Neurotherapeutics, a high‑impact peer‑reviewed journal, reinforcing the scientific credibility of its development pipeline. In a 12‑week Phase I/II open‑label study of 14 children with chronic, relapsing PANS, NTI164 was well tolerated and delivered statistically significant improvements across key disease domains including overall disease severity, anxiety, obsessive‑compulsive symptoms, tics, ADHD symptoms and quality of life. Multi‑omics analyses showed that PANS is associated with widespread dysregulation of epigenetic, ribosomal and immune pathways, which were significantly normalised following NTI164 treatment, providing molecular evidence that the drug modulates core disease mechanisms. Publication of both the clinical outcomes and mechanistic data in a leading journal is being positioned by management as an important validation step that strengthens NTI164’s scientific foundation and underpins its continued development for PANS and other paediatric neuroinflammatory indications, potentially enhancing Neurotech’s standing among clinicians, regulators and investors in the paediatric neurology space.
The most recent analyst rating on (AU:NTI) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Neurotech International stock, see the AU:NTI Stock Forecast page.
More about Neurotech International
Neurotech International is an ASX-listed, clinical‑stage biopharmaceutical company focused on paediatric neurological and neuroinflammatory disorders. Its lead product, NTI164, is a broad‑spectrum oral cannabinoid therapy being developed across indications including autism spectrum disorder, PANDAS/PANS, Rett syndrome and spastic cerebral palsy, where the company has already reported clinically meaningful and statistically significant outcomes in several early‑stage trials with a favourable safety profile.
Average Trading Volume: 915,566
Technical Sentiment Signal: Sell
Current Market Cap: A$18.15M
For an in-depth examination of NTI stock, go to TipRanks’ Overview page.